Phoenix, Arizona–(Newsfile Corp. – April 6, 2021) – The Stock Day Podcast welcomed Avivagen (OTCQB: VIVXF) (“the Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. CEO of the Company, Kym Anthony, joined Stock Day host Everett Jolly.
Jolly began the interview by asking about the Company’s background and current projects. “What we are is a healthtech company that discovered a very interesting product that is made from beta carotene, but has no beta carotene in it and has tremendous health effects ranging from improving and priming the immune system to a very active anti-inflammatory,” explained Anthony.
Jolly then commented on the Company’s recent announcements regarding OxC-beta™ Livestock.”We have three vertical markets; one, where we are furthest advanced, is in livestock,” said Anthony. “We’re in all of the various livestock sectors. The other is companion animals, where last year we launched a companion animal product as a joint venture with Dr. Tobias, which really help with inflammation and joint health for animals, as well as their immune system,” he explained. “Just last month, we launched a human nutraceutical product,” shared Anthony. “We launched it on Amazon with a joint venture with Dr. Tobias; it’s under their brand called, Beta Blend,” he continued. “It is designed to help with immune systems and as an anti-inflammatory.”
“People are looking for where their diets are deficient, where they need superfoods, and this is one of those products that fits squarely into those categories,” said Anthony. “It’s anti-inflammatory action is several times more aggressive than glucosamine and is a wonderful immune enhancer.”
The conversation then turned to the Company’s accomplishments over the past year, as well as their goals moving forward. “In February, we completed a financing, which was 50% over subscribed at an increased amount. So, the market has been very receptive to us and understands the story,” shared Anthony. “It was not a private placement, and it was a very successful deal,” he added. “We’ve also had significant announcements of sales, which are starting to fall like dominoes,” said Anthony. “We did several commercial trials on farms in Mexico, both swine farms and dairy cattle farms; the dairy sector is very interesting in that the dairy farm trials found a significant reduction in bacteria.”
“We announced two significant sales contracts, including one for 10 tonnes of our product to a company called Melder and another 6 tonnes to a company called Transformadora, and we’ve got more that we will be announcing in the near future,” said Anthony. “We have just granted our partner in Mexico, MIG, permission to go and get registration in Costa Rica and four South American countries so that they can take their success in Mexico and transport it elsewhere.”
“One of the other things that has been very helpful is that we got caught up on publishing papers in peer review journals, which is a big deal for our customers and investors,” continued Anthony. “A trial for sows was published in the British Journal of Nutritional Science, which showed that the quality in colostrum from milk and bacteria count were greatly enhanced,” he explained. “A very large dairy trial was conducted in New Zealand and was released last year, which resulted in the Mexican dairy operations trialing the product. It was really a terrifically successful trial.”
“We also published a paper in Poultry Science showing the benefits of trace amounts of our product for broilers,” said Anthony. “These are very important milestones for us,” he added. “Looking forward, we should see an acceleration of that growth in revenues.”
“What do you see as the big difference in the company now versus 12 months ago?”, asked Jolly. “We were getting one-off sales from customers and now we’re getting large purchase orders,” said Anthony. “We’re seeing that coming with increasing frequency where customers are making commitments into the future,” he added. “Our existing customers, whether they are in the Philippines or Thailand, even where they have started small, we’re seeing them increasing in their order frequency and their order amounts.”
“What do you think are the biggest challenges and opportunities that you’ll face here in the next two to three quarters?”, asked Jolly. “In the next two to three quarters it’s really not challenges, but delivering on our purchase order commitments and turning our successful trials, and they’ve all been successful, into purchase order commitments.”
“We’re no longer proving our product, we’re realizing sales, we’ve got discussions underway with large distribution companies and jurisdictions that we’re not in, and we’re realizing sales increasingly in areas that we are in,” closed Anthony.
To hear Kym Anthony’s entire interview, follow the link to the podcast here: https://audioboom.com/posts/7838188-avivagen-discusses-significant-purchase-orders-for-oxc-beta-livestock-with-the-stock-day-podcast.
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.
About OxC-beta™ Technology and OxC-beta™ Livestock
Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about β-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Australia and Malaysia.
Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.
This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions. Statements about OxC-beta’s ability to replace antibiotics commonly added to livestock feeds or to fulfill the global mandate to remove in-feed antibiotics as growth promoters, are forward looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, Avivagen’s products may not the gain market acceptance or regulatory approvals necessary to fulfill the global mandate to remove in-feed antibiotics as growth promoters. Readers are referred to Avivagen’s latest annual information form and management’s discussion and analysis available at www.sedar.com for a discussion of risks associated with its business. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Copyright © 2021 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.
Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6
Head Office Phone: 613-949-8164
About The “Stock Day” Podcast
Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.
Stock Day Media